p53 Transdominance but no gain of function in mouse brain tumor model

Cancer Research

Volumn 60, Issue 11, 2000, Pages 3019-3024

  Hegi, Monika E ^a,b   Klein, Michael A ^b   Rüedi, Daniela ^b   Chène, Patrick ^c   Hamou, Marie France ^a   Aguzzi, Adriano ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Oncology Department   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CANCER INVASION; CONTROLLED STUDY; EMBRYO; FEMALE; GENE ACTIVITY; GENE FUNCTION; GENE LOSS; GENE MUTATION; GENE TARGETING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSACTIVATION;

ALLELES; ANIMALS; BRAIN; BRAIN NEOPLASMS; CELLS, CULTURED; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, DOMINANT; GENES, P53; GENOTYPE; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PHENOTYPE; PLASMIDS; PRECIPITIN TESTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034214086     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
2. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-311, 1997.
3. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923-935, 1992.
4. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
5. Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., and Giaccia, A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (Lond.), 379: 88-91, 1996.
6. El Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parson, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1 a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
7. Forrester, K., Lupold, S. E., Ott. V. L., Chay, C. H., Band, V., Wang, X. W., and Harris, C. C. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene, 10: 2103-2111, 1995.
8. Crook, T., Marston, N. J., Sara, E. A., and Vousden, K. H. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell, 79: 817-827, 1994.
9. Friedlander, P., Haupt, Y., Prives, C., and Oren, M. A mutant p53 that discriminates between p53 responsive genes cannot induce apoptosis. Mol. Cell. Biol., 16: 4961-4971, 1996.
10. Shaulian, E., Zauberman, A., Milner, J., Davies, E. A., and Oren, M. Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation. EMBO J., 12: 2789-2797, 1993.
11. Chène, P., Mittl, P., and Grütter, M. In vitro structure-function analysis of the β-strand of 326-333 of human p53. J. Mol. Biol., 273: 873-881, 1997.
12. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. Gain of function mutations in p53. Nat. Genet., 4: 42-45, 1993.
13. Gualberto, A., Aldape, K., Kozakiewicz, K., and Tlsty. T. D. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc. Natl. Acad. Sci. USA, 95; 5166-5171, 1998.
14. Watanabe, K., Tachibana, O., Sato, K., Yonekawa, Y., Kleihues, P., and Ohgaki, H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol., 6: 217-224, 1996.
15. Kleihues, P., Schäuble, B., zur Hausen, A., Estève, J., and Ohgaki, H. Tumors associated with p53 germline mutations - a synopsis of 91 families. Am. J. Pathol., 150: 1-13, 1997.
16. Bögler, O., Huang, H-J. S., and Cavenee, W. K. Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilities their in vitro transformation. Cancer Res., 55: 2746-2751, 1995.
17. Lühbe, J., von Ammon, K., Watanabe, K., Hegi, M. E., and Kleihues, P. Familial brain tumor syndrome associated with a p53 germline deletion of codon 236. Brain Pathol., 5: 15-23, 1995.
18. Chène, P., Ory, K., Rüedi, D., Soussi, T., and Hegi, M. E. Functional analyses of a unique p53 germline mutant (Y236Δ) associated with a familial brain tumor syndrome. Int. J. Cancer, 82: 17-22, 1999.
19. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr., Butel, J. S., and Bradley. A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature (Lond.), 356: 215-221, 1992.
20. Miller, A. D., and Rosman, G. J. Improved retroviral vectors for gene transfer and expression. Biotechniques, 7: 980-990, 1989.
21. Markowitz, D., Goff, S., and Bank, A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol., 62: 1120-1124, 1988.
22. Pennica, D., Goeddel, D. V., Hayflick, J. S., Reich, N. C., Anderson, C. W., and Levine, A. J. The amino acid sequence of murine p53 determined from a cDNA clone. Virology, 134: 477-482, 1984.
23. Timme, T. L., and Thompson, T. C. Rapid allelotype analysis of p53 knock-out mice. Biotechniques, 17: 461-463, 1994.
24. Hegi, M. E., Söderkvist, P., Foley, J. F., Schoonhoven, R., Swenberg, J. A., Maronpot, R. R., Anderson, M. W., and Wiseman, R. W. Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis (Lond.), 14: 803-810, 1993.
25. Midgley, C. A., Owens, B., Briscoe, C. V., Brynmor Thomas, D., Lane, D. P., and Hall, P. A. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J. Cell Sci., 108: 1843-1848, 1995.
26. Isenmann, S., Brandner, S., Sure, U., and Aguzzi, A. Telencephalic transplants in mice: characterization of growth and differentiation patterns. Neuropathol. Appl. Neurobiol., 22: 108-117, 1996.
27. Wang, Y., Farmer, G., Soussi, T., and Prives, C. Xenopus laevis p53 protein: sequence-specific DNA binding, transcriptional regulation and oligomerization are evolutionary conserved. Oncogene, 10: 779-784, 1995.
28. Milner, J., and Medcalf, E. A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell, 65: 765-774, 1991.
29. Hall, A. R., and Milner, J. Structural and kinetic analysis of p53-DNA complexes and comparison of human and murine p53. Oncogene, 10: 561-567, 1995.
30. Harvey, M., Vogel, H., Morris, D., Bradley, A., Bernstein, A., and Donehower, L. A. A mutant p53 transgene accelerates tumor development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet., 9. 305-311, 1995.
31. Birch, J. M., Blair, V., Kelsey, A. M., Evans, D. G., Harris, M., Tricker, K. J., and Varley, J. M. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene, 17: 1061-1068, 1998.
32. Oda, H., Zhang, S., Zurutani, N., Shimizu, S., Nakatsuru, Y., Aizawa, S., and Ishikawa, T. Loss of p53 is an early event in induction of brain tumors in mice by transplacental carcinogen exposure. Cancer Res., 57. 646-650, 1997.
33. Maddalena, A., Hainfellner, J., Hegi, M. E., Glatzel, M., and Aguzzi, A. No complementation between TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice. Brain Pathol., 9: 627-637, 1999.
34. Albertoni, M., Daub, D. M., Ardem, K. C., Viars, C. S., Powell, C., and Van Meir, E. G. Genetic instability leads to loss of both p53 alleles in human glioblastoma. Oncogene, 16: 321-326, 1998.
35. Harvey, M., Sands, A. T., Weiss, R. S., Hegi, M. E., Wiseman, R. W., Pantazis, P., Giovanella, B. C., Tainsky, M. A., Bradley, A., and Donehower, L. A. In vitro characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene, 8: 2457-2467, 1993.
36. Aguzzi, A., Kleihues, P., Heckl, K., and Wiestler, O. D. Cell type-specific tumor induction in neural transplants by retrovirus-mediated oncogene transfer. Oncogene, 6: 113-118, 1991.
37. Ohgaki, H., Schäuble, B., zur Hausen, A., von Ammon, K., and Kleihues, P. Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch., 427: 113-118, 1995.
38. Ho, Y. S., Hsieh, L. L., Chen, J. S., Chang, C. N., Lee, S. T., Chiu, L. L., Chin, T. Y., and Cheng, S. C. p53 mutation in cerebral primitive neuroectodermal tumors in Taiwan. Cancer Lett., 104: 103-113, 1996.
39. Reifenberger, J., Janssen, G., Weber, R. G., Bostrom, J., Engelbrecht, V., Lichter, P., Borchard, F., Gobel, U., Lenard, H. G., and Reifenberger, G. Primitive neuroectodermal tumors of the cerebral hemispheres in two siblings with TP53 germline mutation. J. Neuropathol. Exp. Neurol., 57: 179-187, 1998.
40. Nozaki, M., Tada, M., Matsumoto, R., Sawamura, Y., Abe, H., and Iggo, R. D. Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system-reappraisal by yeast functional assay. Acta Neuropathol., 95: 291-296, 1998.
41. Shafarenko, M., Mahler, J., Cochran, C., Kisielewski, A., Golding, E., Wiseman, R., and Goodrow, T. Similar incidence of K-ras mutations in lung carcinomas of FVB/N mice and FVB/N mice carrying a mutant p53 transgene. Carcinogenesis (Lond.), 18: 1423-1426, 1997.
42. Kleihues, P., Burger, P. C., and Scheithauer, B. W. The new WHO classification of brain tumours. Brain Pathol., 3: 297-306, 1993.